Education
About Us
Working with TipRanks
Follow Us
JOINN Laboratories (China) Co., Ltd. Class H (HK:6127)
:6127
RESEARCH TOOLSreports
6127 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$6.31 - HK$28.70
Previous CloseN/A
Volume546.17K
Average Volume (3M)7.95M
Market Cap
HK$24.88B
Enterprise ValueHK$7.90B
Total Cash (Recent Filing)HK$2.17B
Total Debt (Recent Filing)HK$21.00M
Price to Earnings (P/E)41.3
Beta1.57
Next Earnings
Aug 27, 2025EPS Estimate
0.13Last Dividend Ex-Date
Jun 26, 2025Dividend Yield0.15%
Share Statistics
EPS (TTM)0.05
Shares Outstanding118,995,210
10 Day Avg. Volume8,738,254
30 Day Avg. Volume7,951,270
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$14.30Price Target Upside-38.36% Downside
Rating ConsensusHold
Number of Analyst Covering0
JOINN Laboratories (China) Co., Ltd. Class H News
6127 FAQ
What was JOINN Laboratories (China) Co., Ltd. Class H’s price range in the past 12 months?
JOINN Laboratories (China) Co., Ltd. Class H lowest stock price was HK$6.31 and its highest was HK$28.70 in the past 12 months.
What is JOINN Laboratories (China) Co., Ltd. Class H’s market cap?
JOINN Laboratories (China) Co., Ltd. Class H’s market cap is HK$24.88B.
When is JOINN Laboratories (China) Co., Ltd. Class H’s upcoming earnings report date?
JOINN Laboratories (China) Co., Ltd. Class H’s upcoming earnings report date is Aug 27, 2025 which is in 24 days.
How were JOINN Laboratories (China) Co., Ltd. Class H’s earnings last quarter?
JOINN Laboratories (China) Co., Ltd. Class H released its earnings results on Apr 29, 2025. The company reported HK$0.053 earnings per share for the quarter, missing the consensus estimate of HK$0.109 by -HK$0.056.
Is JOINN Laboratories (China) Co., Ltd. Class H overvalued?
According to Wall Street analysts JOINN Laboratories (China) Co., Ltd. Class H’s price is currently Overvalued.
Does JOINN Laboratories (China) Co., Ltd. Class H pay dividends?
JOINN Laboratories (China) Co., Ltd. Class H pays a Annually dividend of HK$0.036 which represents an annual dividend yield of 0.15%. See more information on JOINN Laboratories (China) Co., Ltd. Class H dividends here
What is JOINN Laboratories (China) Co., Ltd. Class H’s EPS estimate?
JOINN Laboratories (China) Co., Ltd. Class H’s EPS estimate is 0.13.
How many shares outstanding does JOINN Laboratories (China) Co., Ltd. Class H have?
JOINN Laboratories (China) Co., Ltd. Class H has 118,995,210 shares outstanding.
What happened to JOINN Laboratories (China) Co., Ltd. Class H’s price movement after its last earnings report?
JOINN Laboratories (China) Co., Ltd. Class H reported an EPS of HK$0.053 in its last earnings report, missing expectations of HK$0.109. Following the earnings report the stock price went up 0.832%.
Which hedge fund is a major shareholder of JOINN Laboratories (China) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6127
JOINN Laboratories (China) Co., Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
HK$14.30 (-38.36% Downside)
HK$14.30 (-38.36% Downside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
219.29%
12-Months-Change
Fundamentals
Return on Equity
4.83%
Trailing 12-Months
Asset Growth
-4.06%
Trailing 12-Months
Company Description
JOINN Laboratories (China) Co., Ltd. Class H
JOINN Laboratories (China) Co., Ltd. Class H (6127) is a leading contract research organization (CRO) in China, specializing in providing preclinical and clinical research services. The company operates primarily in the pharmaceutical and biotechnology sectors, offering a wide range of services including drug discovery, development, and regulatory submissions. With a focus on innovation and quality, JOINN Laboratories supports clients in bringing their products to market efficiently and effectively.
Technical Analysis
Sino Biopharmaceutical
―
Wuxi Biologics (Cayman)
―
China Resources Pharmaceutical Group Ltd.
―
Livzon Pharmaceutical Group
―
CSPC Pharmaceutical Group
―
Ownership Overview
―
Insiders
3.00%
Mutual Funds
0.78% Other Institutional Investors
93.20% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---